“Pediatric rare disease trials continue to face significant hurdles: high costs, long timelines, and endpoints that often lack the sensitivity to capture clinically meaningful change. DiMe’s initiative to define a core set of high-value digital measures is an important step toward more efficient, patient-centric, and evidence-driven development. At Clouds of Care, we were proud to contribute our expertise in neurophysiological measures, particularly EEG. We see EEG as a powerful and underutilized tool that goes beyond seizure counts to provide objective, quantifiable insights into brain function. Integrating these signals alongside other digital measures can improve endpoint sensitivity, reduce trial burden, and ultimately increase the probability of success in clinical development. Supporting initiatives like this closely aligns with our mission: advancing smarter, data-driven approaches that make clinical research more meaningful for patients and more effective for sponsors.”

– Pieter van Mierlo | Chief Scientific Officer, Clouds of Care